Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in ...

Moderna said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant. The company said a preliminary analysis from a phase four clinical ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

Moderna shares were down 7.4% Friday—their lowest level since March 2020. The drop brought the drugmaker’s year-to-date slump ...

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary ...

The report says officials plan to include the claim in a presentation next week to a key vaccine panel that advises the CDC ...

Pfizer (PFE) and Moderna (MRNA) reveal trial data showing their updated COVID mRNA vaccines are safe and effective after ...

A little less than a year after targeting Moderna in an mRNA vaccine patent lawsuit, GSK is widening the scope of its ...

Speaking at a WIRED event Tuesday, Moderna CEO Stéphane Bancel said he was “encouraged” by the company’s dialogue with the ...

Access to the COVID-19 vaccine may be changing soon in the Mid-Ohio Valley. U.S. Health Secretary Robert F. Kennedy Jr. and ...

Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 International Congress of Inborn Errors of ...